within Pharmacolibrary.Drugs.R_RespiratorySystem.R03A_AdrenergicsInhalants.R03AL07_FormoterolAndGlycopyrroniumBromi;

model FormoterolAndGlycopyrroniumBromi
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 1.6666666666666667e-05,
    adminDuration = 600,
    adminMass = 5 / 1000000,
    adminCount = 1,
    Vd = 0.083,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
info       = "<html><body><table><tr><td>name:</td><td>FormoterolAndGlycopyrroniumBromide</td></tr><tr><td>ATC code:</td><td>R03AL07</td></tr><td>route:</td><td>inhalation</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Formoterol and glycopyrronium bromide is a fixed-dose combination of a long-acting beta2-adrenergic agonist (formoterol) and a long-acting muscarinic antagonist (glycopyrronium). It is used as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD). The combination is approved for use in several countries for the management of airflow limitation in COPD.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for typical adult patients with COPD after inhaled administration, based on data of separate components and regulatory summaries. No direct published population PK models found for the fixed-dose combination product.</p><h4>References</h4><ol><li><p>Kuna, P, et al., &amp; Ciurlia, G (2022). Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma. <i>Pharmacology research &amp; perspectives</i> 10(4) e980–None. DOI:<a href=\"https://doi.org/10.1002/prp2.980\">10.1002/prp2.980</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35733414/\">https://pubmed.ncbi.nlm.nih.gov/35733414</a></p></li><li><p>Chen, Q, et al., &amp; Dorinsky, P (2019). Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. <i>Clinical therapeutics</i> 41(5) 897–909.e1. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2019.03.007\">10.1016/j.clinthera.2019.03.007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30982547/\">https://pubmed.ncbi.nlm.nih.gov/30982547</a></p></li><li><p>Dorinsky, P, et al., &amp; Reisner, C (2018). Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent. <i>Pulmonary pharmacology &amp; therapeutics</i> 51 18–25. DOI:<a href=\"https://doi.org/10.1016/j.pupt.2018.05.001\">10.1016/j.pupt.2018.05.001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29763659/\">https://pubmed.ncbi.nlm.nih.gov/29763659</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R03AL07 folded in (Drugs.ATC removed)</li><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end FormoterolAndGlycopyrroniumBromi;
